Literature DB >> 9246024

Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients.

J M Prins1, G J Weverling, R J van Ketel, P Speelman.   

Abstract

Animals show a faster clearance and a lower incidence of nephrotoxicity and ototoxicity when aminoglycosides are administered during the activity period. Human data on a circadian rhythm in pharmacokinetics are conflicting, and there are no data on a circadian rhythm in toxicity. When aminoglycosides are administered once daily, as is often done, a circadian rhythm in pharmacokinetics or toxicity could have clinical implications. In a prospective study we investigated the influence of drug administration time on serum drug levels and the incidence of nephrotoxicity in 221 patients with serious infections treated with gentamicin or tobramycin once daily. We did not find statistically significant differences in trough or peak levels for the three time periods (midnight to 7:30 AM, 8 AM to 3:30 PM, and 4 to 11:30 PM). Nephrotoxicity occurred significantly more frequently when the aminoglycosides were administered during the rest period (midnight to 7:30 AM; p = 0.004). In addition to the coadministration of high-dose furosemide or other nephrotoxic antibiotics and the duration of treatment, the time of administration was still an independent risk factor in a multivariate analysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246024     DOI: 10.1016/S0009-9236(97)90156-9

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration.

Authors:  M LeBrun; L Grenier; P Gourde; M G Bergeron; G Labrecque; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Timing is important in medication administration: a timely review of chronotherapy research.

Authors:  Gagandeep Kaur; Craig Phillips; Keith Wong; Bandana Saini
Journal:  Int J Clin Pharm       Date:  2013-01-18

Review 3.  Clinical pharmacokinetics and pharmacodynamics of isepamicin.

Authors:  M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 4.  Pharmacological considerations for the proper clinical use of aminoglycosides.

Authors:  Spyridon Pagkalis; Elpis Mantadakis; Michael N Mavros; Christina Ammari; Matthew E Falagas
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

Review 5.  Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring.

Authors:  R L Slaughter; D M Cappelletty
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

6.  Chronopharmacokinetics of once daily dosed aminoglycosides in hospitalized infectious patients.

Authors:  Erik van Maarseveen; Wai Hong Man; Johannes Proost; Cees Neef; Daniël Touw
Journal:  Int J Clin Pharm       Date:  2015-01-24

7.  Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients.

Authors:  A Abdel-Bari; M Sherif Mokhtar; Nagwa Ali Sabry; Sanaa Abd El-Shafi; Naglaa Samir Bazan
Journal:  Saudi Pharm J       Date:  2010-11-04       Impact factor: 4.330

Review 8.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

Review 10.  Aminoglycosides: nephrotoxicity.

Authors:  M P Mingeot-Leclercq; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.